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State of the Art Lectu re 
Chimaerism after whole organ 
transplantation 
T.E.STARZL 
Throughout the modern history of transplantation, progress with kidney and 
liver grafting has been interchangeable - and then applicable with very little 
change to the thoracic organs and most recently the intestine. I will focus 
today first on why any kind of whole organ allograft and xenograft is accepted. 
because this not only defines the state of the art for the liver. but predicts 
the future of transplantation as a whole. 
My personal interest in transplantation came via the back door of 
physiology, during metabolic investigations of the special (so-called 
hepatotrophic) qualities of portal venous blood. In the course of these 
inquiries I first developed a new experimental method of total hepatectomy 1 
and then the operation of liver replacement1 . By the end of 1959 we had 
clarified the surgical secrets of liver transplantation and had also completed 
a second project in dogs with a multivisceral transplant procedureJ . Twenty-five 
years later this latter operation was performed successfully in humans and 
became the basis for several variations such as the cluster and liver-intestine 
procedures4 . 
However, this research activity in 1958 through early 1960 was in a 
therapeutic vacuum because there was no such thing as practical immunosup-
pression. Pharmacological immunosuppression is dated to the classical paper 
on 6-mercaptopurine by Schwartz and Dameshek 5 in a non-transplant model. 
Within a few months this drug was shown to prolong survival of skin grafts 
in rodents6 •7 and kidney allografts in dogs8.9. Realizing by now that the 
road to my primary objective of liver transplantation would have to be 
through the simpler kidney transplant model, I moved from Northwestern 
University in Chicago to the University of Colorado in late 1961. There I 
began a clinical kidney programme. 
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KIDNEY TRANSPLANTATION AND CHIMAERISM 
The programme was based on the simple laboratory discovery that canine 
kidney rejection under azathioprine could be reversed with prednisone in 
88% of dogs iO , an incidence that proved to be the same in humans, as we 
reported in 1963 1 1. The key points were summarized in the title of the 1963 
article - the reversal of kidney rejection by steroids and the subsequent ability 
in successful cases to later reduce the intensity of immunosuppression (referred 
to as 'tolerance'). 
The explanation for these two observations was a mystery in 1963, but in 
retrospect a clue to the mystery was uncovered with exhaustive skin test 
studies (tuberculin, histoplasmin, coccidiodin, etc.) performed on these early 
Colorado kidney recipients and their donors. Skin reactions that were positive 
in the donor but not the recipient were found to cross over to the previously 
negative recipient along with the transplanted kidney 77% of the time. When 
this did not occur (the other 23%), it meant that the kidney transplant had 
failed. Wilson and Kirkpatrick, the immunology fellows who performed these 
tests. speculated (as it turned out correctly) that the migration of the skin 
tests was 'caused by adoptive transfer of donor cellular immunity by 
leukocytes in the renal graft vasculature and hilar lymphoid tissue'12. 
That this actually had occurred was proved 29 years later when some of 
these original kidney recipients were restudied, proving that there had been 
an exchange of lymphodendritic leucocytes between the transplanted kidneys 
and their recipients. These cells still survived nearly three decades later. The 
presence of the donor cells in the lymph nodes and skin of four recipients 
of kidneys from HLA mismatched donors was shown with immunocytochemical 
techniques that stained cells of donor phenotype. These appeared to be 
dendritic cells. The microchimaerism was confirmed with polymerase chain 
reaction techniques. In a fifth patient. a female who had received a kidney 
from her father, male donor cells with the Y chromosome were found in 
recipient tissues with fluorescent in situ hybridization. and confirmed with 
polymerase chain reaction (peR) techniq ues. All of the studied recipients 
and their grafts were composite structures - no longer the same as at the outset 13. 
LIVER TRANSPLANT RECIPIENTS 
This was only the beginning of what quickly became a scientific detective 
story. Between April and July of 1992 evidence was obtained that an even 
more extensive exchange oftissue leucocytes occurred after liver transplantation, 
creating a composite graft as well as chimaeric composite host on an even 
larger scale than after kidney transplantation 14 . For the liver study we began 
by obtaining follow-ups on all 44 of our first 206 liver recipients who still 
were alive 1 O~ to nearly 23 years after transplantation. Six of these patients 
had stopped their immunosuppressive medications 1-6 years after transplan-
tation and had been drug-free for 5-13 years. The lymphocytes of treated 
as well as untreated patients reacted vigorously to the lymphocytes of 
third-party donors. The drug-free patients had achieved lasting immunological 
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tolerance. We also realized that many if not most of those still being treated 
probably no longer required immunosuppression. 
Multiple biopsies were performed on six of the drug-free patients and on 
16 more still under maintenance immunosuppression. Specimens were taken 
of the liver. skin. and a convenient lymph node. Using HLA markers. all 22 
were demonstrated to be chimaeras with immunocytochemical and PCR 
techniques; by PCR, 75% were also blood chimaeras. This could also be 
documented with sex typing in a subgroup of nine women who had received 
livers from male donors. Sex chimaerism (the Y chromosome) was detected 
with fluorescent in situ hybridization or with PCR in every case. Using either 
the H LA alleles of chromosome 6 or the male Y chromosome, the hepatocytes. 
ducts. and endothelial cells of the allografts remained donor-specific while 
the KuptTer cells. dendritic cells and other stromal leucocytes were those of 
the recipients. The systemic chimaerism was usually in more than one site. 
In one female patient who lost her male graft after 12 years to recurrent viral 
hepatitis. tissue samples taken at retransplantation (which was successful) 
showed male cells in blood. skin. lymph nodes. jejunum and the aortic ellipse 
excised to accommodate a Carrel patch. At the time these samples were 
collected. this woman had been otT medication for 7 years. In the autopsy 
specimens from another patient who died of B virus hepatitis after 18.4 years. 
chimaerism was found in essentially all tissues of the body! s. 
Aside from their immunological implications the peripheralized chimaeric 
cells can profoundly alter metabolism!6. In three additional patients who 
had undergone liver transplantation 26-91 months previously for metabolic 
storage diseases, enzyme transport by the seeded peripheral cells explained 
how amylopectin (in two patients with GSD IV) could be absorbed from 
the heart as had occurred. Donor cells (thought to be dendritic leucocytes) 
were detected with monoclonal anti-HLA antibodies and PCR in the 
myocardium. skin, and lymph nodes. In a patient with Gaucher's disease, 
donor cells or donor DNA were found in the recipient blood, bone marrow, 
skin, small bowel. and lymph nodes. [n this patient the glucocerebroside 
deposits (Gaucher's cells) in the lymph nodes had diminished astonishingly 
over the 26 months post-transplantation. 
Thus systemic chimaerism was detected in all 25 liver recipients who were 
studied from 2 to more than 20 years post-transplantation. The ability to 
find donor cells wherever they were looked for was striking. Because the 
same thing was found in the kidney recipients. although less prominently, 
we concluded that the same thing probably occurred with all kinds of grafts 
- but so much more extensively with the liver than with other organs. that 
this accounted for what has been called hepatic tolerogenicity. 
WHY PRINCIPLES OF IMMUNOSUPPRESSION ARE NOT DRUG-
OR ORGAN-SPECIFIC 
These remarkable discoveries in kidney and liver recipients were made only 
a few months ago. Of course. none of this was known in 1963 when. without 
knowing why. the observations of rejection reversal and so-called tolerance 
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in kidney recipients led to the empirical therapeutic dogma upon which the 
transplantation of all whole organ transplantation is based 11.1"7. The dogma 
calls for daily baseline treatment (in those early days with azathioprine) plus 
intervention with the highly dose-manoeuvrable adrenal cortical steroids 
(later augmented with antilymphoid agents) to whatever level is required to 
maintain stable graft function. This creates a trial-and-error situation for 
every patient as drugs are weaned. 
Although the new drugs that have been added through the years have 
been increasingly potent, they can be viewed as traffic directors, allowing 
the cell movement to and from all kinds of grafts but preventing the immune 
destruction that is the natural purpose of the traffic. Apparently, it does not 
matter exactly how the immune reaction is disrupted, but only that this be 
achieved without killing all of the migratory cells. The emasculated but living 
cells that normally cause graft immunogenicity and rejection become instead 
the missionaries subserving chimaerism, graft acceptance, and ultimately 
tolerance. Disruption of the function of the lymphocyte can be at the level 
of antigen processing (claimed for the experimental drug, deoxyspergualin), 
at an early stage in T-cell activation as occurs with cyclosporin and FK 506, 
or distal to this with rapamycin which does not inhibit the secretion of 
cytokines including IL-2 but blocks their action. The so-called anti proliferative 
drugs (of which azathioprine was the prototype) work even more distally. 
RE-EXAMINING TRANSPLANTATION IMMUNOLOGY 
With the understanding that cell migration and repopulation is the basis of 
graft acceptance. no matter what the organ. we now can re-examine some 
controversies in transplantation immunology that have never been resolved 
- including why HLA tissue matching to govern the distribution of cadaveric 
organs has been so imperfect a tool. To understand these controversies we 
must turn the pages back 50 years, to when Peter Medawar planted the seed 
of our clinical specialty. If rejection was an immunological response. as 
Medawar claimed in 1944 18 , what could be more logical in preventing it 
than to weaken the immune system. By 1951, Billingham. Krohn. and 
Medawar 19 and the American Morgan20 had taken this crucial step. and 
had shown that skin graft survival was prolonged with cortisone acetate and 
ACTH - the first immunosuppressive drugs. The year before. Dempster and 
co-workers. of Hammersmith. showed mitigation of skin graft rejection with 
total-body irradiation 21 . 
Seemingly. these were small steps. but then in 1953 Billingham. Brent. and 
Medawar""·23 raised expectations to a new level by showing the possibility 
of acquiring immunological tolerance. albeit only under the special circumstance 
of inoculation of immunocompetent adult spleen cells into fetal and perinatal 
mice. Main and Prehn24 were able to mimic these developmental conditions 
in adult mice using supralethal total-body irradiation and bone marrow 
allo-reconstltution. When the reconstituted mice were shown to be tolerant 
to donor strain skin (the white patch). the clinical possibility of creating 
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radiation bone marrow chimaeras as a means to the end of solid organ 
transplantation seemed obvious. 
These hopes were promptly dashed when the concept of GVHD and runt 
disease was delineated by Billingham and Brent2s . However, what was not 
clearly recognized, then or later, was that these whole-animal models. and 
subsequently the experimental F 1 hybrid model, are almost artifacts in the 
sense that the interactions of the two-way cell migration and repopulation 
that I have been discussing were precluded in each case: by the immature 
state of one party (that was the Billingham, Brent, Medawar model), by the 
cytoablation used by Main and Prehn (and later bone marrow transplanters), 
or by genetic manipulation (the F 1 hybrid model). These were whole-animal 
analogues of the in viero one-way mixed-lymphocyte reaction. 
DIVISION OF TRANSPLANTATION INTO TWO FIELDS 
Of course, this is hindsight 33 years later. Between 1959 and 1963 - and 
without really knowing why - the intellectual root that came from Medawar's 
seed divided into two branches. Although the issue from the roots looked 
like two separate trees when they surfaced the differences merely reflected 
different therapeutic dogmas. The bone marrow tree with its precondition 
of cytoablation mimicked the Billingham, Brent, Medawar model and was 
the in vivo version of a one-way MLR. HLA matching was crucial. 
Engraftment in a drug-free state (called tolerance) was a realizable objective 
only with perfect matching. This was not achieved clinically until 1968 26•27 , 
but even with MHC compatibility, GVHD was a constant threat. The reason 
for the virulence of the GVHD with an HLA mismatch was the complete 
removal of a counterweight to the transplanted immunocytes. 
The whole-organ transplanters who had broken ranks with their bone 
marrow colleagues, empirically developed the long-term immunosuppression 
which I discussed earlier with which success (called graft acceptance, not 
tolerance) did not depend on matching and could be accomplished without 
GVHD - even after the transplantation of lymphoid-rich organs such as the 
intestine and liver. The explanation for the GVHD resistance with the whole 
organs is envisioned as the interaction of cells coming out from the allograft 
with the immunocytes of the recipient (a two-way in vivo MLR). The term 
for the long-term coexistence of two populations of cells is mixed chimaerism. 
Of course, the fact that mixed chimaerism interdicts GVHD is only half 
of the story. The other half is that the midfield cell interaction (which results 
in what we have called mutual natural immunosuppression) also mitigates 
rejection (the host versus graft reaction). The details of this donor - recipient 
rapproachment are not known, but it does seem clear that even organs like 
the kidney with a poor lymphoreticular constituency have enough dendritic 
cells (or whatever these leucocytes are) to sometimes induce for themselves 
donor-specific non-reactivity (tolerance). In the process the donor recipient 
interactions are envisioned as occurring on a sliding scale, in which each 
further level of his to incompatibility provokes variable countervailing increases 
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in the mutually cancelling donor versus recipient and recipient versus donor 
cell reactivity. 
For renal allografts it becomes possible to understand why Terasaki, Opelz, 
and others have shown a large advantage only for six-aritigen matched 
cadaver kidney but not for any matching that is less perfect. Most importantly, 
it becomes possible to understand why the vast majority of unmatched 
kidneys do well. For liver transplantation the reports from Cambridge and 
Pittsburgh become comprehensible that have shown an inverse relation 
between the quality of HLA match and survival of liver recipients, but again 
a difference that is measurable only within a few percentage points. 
INDUCTION OF TOLERANCE 
It seems obvious that the crucial variable distinguishing one organ from 
another is the lymphodendritic (not the parenchymal) component - and that 
these tissue leucocytes can be tolerogenic as well as immunogenic when 
effective immunosuppression is given. The liver, with its dense constituency 
of these cells, is high on the favourable list of tolerogenicity, with the lung 
and intestine following and the heart and kidney bringing up the rear. It is 
self-evident that the underprivileged kidney and heart could be brought to 
the same level of tolerogenicity advantage as the liver by the perioperative 
infusion of lymphoreticular cells obtained from bone marrow of the organ 
donor, or possibly from the spleen. Now the cycle is complete because this 
was the starting point for Billingham, Brent, and Medawar, and then Main 
and Prehn. 
THE DRUG REVOLUTION 
Of course, what I have said today is our current understanding of transplantation. 
Rather than limiting a search for better drugs, this insight should encourage 
their development. as can be illustrated by the different eras of liver 
transplantation. In July 1967 the first long-surviving liver recipients were 
produced under azathioprine, prednisone, after an effort which by then had 
consumed almost 10 years. However. acceptance of the procedure was slow 
over the next dozen years because of its high mortality. Roy Caine's 
introduction of cycJosporin28 and the subsequent combination of this drug 
with prednisone29 allowed a doubling or more of survival about a decade 
ago and brought liver transplantation to centre-stage30 . 
Recently, the liver has been the lead organ in the next step of 
immunosuppression. made possible with the drug, FK 506, whose action is 
similar to cycJosporin31 • The patient and graft survival with FK 506 has 
been improved a further 10-15% compared to the cycJosporin results in the 
Pittsburgh trials. and in the recent European multicentre randomized trials 
of FK 506 versus cycJosporin. 
These trials suggest that we are at the dawn of another era in transplantation, 
signalled in addition by an emerging population of recipients of complete 
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cadaveric small bowel, either transplanted alone, with the liver, or as part 
of a multivisceral graft 32 • Of 23 such patients treated 4 months to more than 
2 years ago, all but three are alive. Only one example of GVHD has been 
seen. The chimaerism I have been discussing has been obvious in every case. 
In the intestine with epithelial cells of the graft remain those of the donor 
while the lymphoreticular stromal substrate switches over to predominantly 
that of the recipient. 
XENOTRANSPLANT ATION 
When organs are transplanted from a significantly disparate species, the first 
immunological hurdle is that of preformed xenospecific antibodies which 
quickly de vascularize the graft and exclude it from recipient circulation by 
damaging its blood vessels33 . If this barrier can be surmounted, the process 
of xenograft acceptance involves the same bidirectional cell migration and 
consequent systemic chimaerism as with allotransplantation. After hamster 
to rat xenotransplantation, the cells displaced from the xenografts can be 
detected in widespread rat recipient tissues with polyclonal rat absorbed 
anti-hamster leucocyte antibodies, and confirmed with PCR techniques t4 . 
As with allotransplantation, the chimaerism is more extensive after liver than 
after heart transplantation. 
Chimaerism was observed recently in a patient who survived for 70 days 
after receipt of a baboon liver. Death was caused by infectious complications 
and by complications of biliary stasis rather than rejection or GVHDJ4 . This 
means that successful clinical xenotransplantation must be visualized along 
the same lines of donor-recipient cellular intimacy which we believe is the 
fundamental means of xenograft as well as allograft acceptance. 
SUMMARY 
I have tried to present a unified view of transplantation to which the liver 
has contributed the central role 35 .36 • Thank you for the honour of allowing 
me to present this to you. 
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